Patents Examined by Patricia L. Morris
  • Crystalline 4-amino-2-(2,6-dioxopiperidine-3-YL)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
    Patent number: 10590103
    Abstract: Provided herein is a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate. Pharmaceutical compositions comprising the crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate are also disclosed.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: March 17, 2020
    Assignee: Celgene Corporation
    Inventor: Jerry Lee Atwood
  • Compounds
    Patent number: 10590125
    Abstract: The present invention relates to compounds which are inhibitors of SSAO activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumor growth.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: March 17, 2020
    Assignee: PROXIMAGEN, LLC
    Inventors: Max Espensen, Lee Patient, David Evans, Edward Savory, Iain Simpson
  • Guanidine compounds and use thereof
    Patent number: 10590081
    Abstract: The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: March 17, 2020
    Assignee: ImmunoMet Therapeutics Inc.
    Inventors: Sung Wuk Kim, Hong Woo Kim, Sang Hee Yoo, Ji Sun Lee, Hye Jin Heo, Hong Bum Lee, Ji Ae Kook, Young Woo Lee
  • Method of producing proton pump inhibitor compound having optical activity
    Patent number: 10589262
    Abstract: A highly pure optically active proton pump inhibitor compound can be produced safely and inexpensively in a high yield and enantioselectivity by a method of producing an optically active sulfoxide of Formula 2 or a salt thereof, comprising oxidizing a sulfide of Formula 1 or a salt thereof with hydrogen peroxide using an iron salt in the presence of a chiral ligand of Formula 3; wherein A is CH or N; R1 is hydrogen atom, an alkyl optionally substituted by halogen(s), or an alkoxy optionally substituted by halogen(s); one to three R2 may exist, and each of R2 is independently an alkyl, a dialkylamino, or an alkoxy optionally substituted by halogen(s) or alkoxy(s); each of R3 is independently hydrogen atom, a halogen, cyano or the like; R4 is a tertiary alkyl; and * and ** represent respectively R configuration or S configuration.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: March 17, 2020
    Assignees: THE UNIVERSITY OF TOKYO, TOWA PHARMACEUTICAL CO. LTD.
    Inventors: Eiichi Nakamura, Laurean Ilies, Yoji Oderaotoshi, Takuhiro Izumi, Shigenobu Nishiguchi
  • Therapeutic compounds and methods of use thereof
    Patent number: 10584108
    Abstract: The invention provides compounds that are useful for treating or preventing cancer.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: March 10, 2020
    Assignee: Kuality Herbceutics LLC
    Inventor: Chengguo Xing
  • 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists
    Patent number: 10584127
    Abstract: Disclosed are chemical entities of Formula (I), wherein R1 and Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: March 10, 2020
    Assignee: Rugen Holdings (Cayman) Limited
    Inventor: Gideon Shapiro
  • N3,N6-bis(2-(5-methoxy-1H-indole-3-yl)ethyl)-2,6-dimethyl-4-(2-nitrophenyl)pyridine-3,5-dicarboxamide and use thereof in the field of neurotoxicity
    Patent number: 10576072
    Abstract: The invention relates to a molecule enabling removal of neurotoxicity observed in neuron cells due to various reasons.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: March 3, 2020
    Inventors: Ahmet Hacimuftuoglu, Orhan Ates, Nurullah Saracoglu, Ali Taghizadehghalehjoughi, Farrokh Lafzi
  • Deuterium-enriched pioglitazone
    Patent number: 10576071
    Abstract: The present application describes deuterium-enriched pioglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: March 3, 2020
    Assignee: Poxel SA
    Inventor: Anthony W. Czarnik
  • (S)-N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
    Patent number: 10577348
    Abstract: A composition comprising (S)—N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide and hypromellose acetate succinate for pharmaceutical preparations, especially capsule preparations.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: March 3, 2020
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Pranav Gupta, Jason Wan, Scott T. Trzaska
  • Galunisertib crystalline form, preparation method thereof and use thereof
    Patent number: 10577372
    Abstract: The present disclosure relates to a novel crystalline form of Galunisertib, processes for preparation and use thereof. The present disclosure also relates to a pharmaceutical composition comprises the novel crystalline form of Galunisertib and use of the novel crystalline form of Galunisertib and pharmaceutical composition for preparing drugs treating disease. The crystalline form of the present disclosure has good stability, solubility and hygroscopicity, which has significant value for future drug optimization and development.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: March 3, 2020
    Assignee: Crystal Pharmaceutical (Suzhou) Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Yuhao Chen, Hui Gao, Fei Lu, Xiaoyu Zhang
  • Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
    Patent number: 10568876
    Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula (I) are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: February 25, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jason Imbriglio, Rui Liang, Clare London, Kenneth Marby, James Tata, Ming You, Yusheng Xiong
  • Diamino pyridine derivatives
    Patent number: 10570096
    Abstract: The present invention describes novel diamino pyridine derivatives exhibiting JAK modulating properties. The present invention also relates to pharmaceutical compositions comprising these novel compounds, methods of using said compounds in the treatment of various diseases and disorders being susceptible to JAK modulation, and processes for preparing the compounds described hereinafter.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: February 25, 2020
    Assignee: Novartis AG
    Inventor: Gebhard Thoma
  • Salt forms of 4-cyano-n-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)pyridin-3-yl)-1H-imidazole-2-carboxamide
    Patent number: 10562892
    Abstract: The present disclosure discusses salt forms of 4-cyano-N-[2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)pyridin-3-yl]-1H-imidazole-2-carboxamide.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: February 18, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Nagy E. Fawzy, David Breslin
  • Crystalline form of lenvantinib mesylate and process of preparation thereof
    Patent number: 10562855
    Abstract: The present disclosure relates to a novel crystalline form of lenvatinib mesylate and the preparation method thereof. The novel crystalline form of mesylate of the present disclosure can be used for treating invasive and differentiated thyroid cancer. The novel crystalline form of mesylate of the present disclosure has good solubility, stability, and remarkable purification effect in process. The preparation method of this novel crystalline form is simple, low cost, and has an important value for future optimization and development of the drug.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: February 18, 2020
    Assignee: CRYSTAL PHARMATECH CO., LTD.
    Inventors: Minhua Chen, Yanfeng Zhang, Xiaojuan Diao, Xiaoyu Zhang
  • Crystalline forms of an androgen receptor modulator
    Patent number: 10556882
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: February 11, 2020
    Assignees: Aragon Pharmaceuticals, Inc., Sloan-Kettering Institute For Cancer Research
    Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Nicotine salts, co-crystals, and salt co-crystal complexes
    Patent number: 10556880
    Abstract: The invention provides certain nicotine salts, co-crystals, and salt co-crystals and provides novel polymorphic forms of certain nicotine salts. In particular, nicotine salts with mucic acid, 3,5-dihydroxybenzoic acid, and 2,3-dihydroxybenzoic acid, and crystalline polymorphic forms of nicotine 4-acetamidobenzoate, nicotine gentisate, and nicotine 1-hydroxy-2-naphthoate are described. The invention further provides methods of preparation and characterization of such nicotine salts, co-crystals, and salt co-crystals and polymorphic forms thereof. In addition, tobacco products, including smoking articles, smokeless tobacco products, and electronic smoking articles comprising nicotine salts, co-crystals, and/or salt co-crystals are also provided.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: February 11, 2020
    Assignee: R.J. Reynolds Tobacco Company
    Inventors: Gary M. Dull, Andrew Carr, Emma Sharp
  • Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
    Patent number: 10550102
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: February 4, 2020
    Assignee: NOVARTIS AG
    Inventors: Christopher M. Adams, Doug Bevan, Michael Paul Capparelli, Takeru Ehara, Luciana Ferrara, Nan Ji, Erik Meredith, Muneto Mogi, James J. Powers, Ganesh Prasanna, Nello Mainolfi, Mitsunori Kato
  • Processes for the preparation of 4-alkoxy-3-hydroxypicolinic acids
    Patent number: 10550083
    Abstract: 4-Alkoxy-3-hydroxypicolinic acids may be conveniently prepared from 4,6-dibromo-3-hydroxypicolinonitrile in a series of chemical steps selected from bromo substitution, nitrile hydrolysis and halogen reduction that are conducted as a single pot process. 4,6-Dibromo-3-hydroxypicolinonitrile may be prepared from furfural in a series of chemical steps selected from cyano-amination, amine salt formation and bromination-rearrangement.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: February 4, 2020
    Assignee: Dow AgroSciences LLC
    Inventors: Kenneth E. Stockman, Gregory T. Whiteker, Erich J. Molitor, Nakyen Choy
  • Third generation taxoids and methods of using same
    Patent number: 10550093
    Abstract: The invention includes taxoid compounds represented by the formula: wherein: R1 represents a methyl group or a fluorine; R2 represents an alkyl or alkenyl group having one to six carbon atoms; or a cycloalkyl or cycloalkenyl group having three to seven ring carbon atoms; R3 represents an alkyl, alkenyl, dialkylamino, alkylamino, or alkoxy group having one to six carbon atoms; a cycloalkyl or cycloalkenyl group having three to seven ring carbon atoms; an aryl group having six to eighteen ring carbon atoms; or a heteroaryl group having three to seventeen ring carbon atoms; R4 represents hydrogen or a methyl group; and X represents hydrogen or fluorine.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: February 4, 2020
    Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Iwao Ojima, Changwei Wang, Xin Wang
  • Heteroaryl substituted pyridyl compounds useful as kinase modulators
    Patent number: 10544133
    Abstract: Compounds having the following formula: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: January 28, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Rajeev S. Bhide, John V. Duncia, John Hynes, Satheesh Kesavan Nair, William J. Pitts, Sreekantha Ratna Kumar, Daniel S. Gardner, Natesan Murugesan, Venkatram Reddy Paidi, Joseph B. Santella, Ramesh Kumar Sistla, Hong Wu